Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study

Journal of Clinical Pharmacology - United States
doi 10.1002/jcph.1362
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Results From the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Clinical Breast Cancer
Cancer ResearchOncology
2019English

Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Disease

2014English

A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine

British Journal of Cancer
Cancer ResearchOncology
2019English

A Phase I Dose-Escalation Study of a Biosimilar Trastuzumab in Chinese Metastasis Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

Cost Analysis Study of Anti-Diabetic Fixed Dose Combination Drugs: An Indian Scenario

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

The Pharmacokinetic Profile of a Novel Fixed-Dose Combination Tablet of Ibuprofen and Paracetamol

BMC Clinical Pharmacology
2010English

Fixed-Dose Combination Therapy for the Prevention of Atherosclerotic Cardiovascular Diseases

Cochrane Database of Systematic Reviews
2017English

Synergistically Active and Safe Fixed Dose Combination of Meropenem and Sulbactam

IIOAB Letters
2013English

Interferon Beta-1a for the Maintenance of Remission in Patients With Crohn's Disease: Results of a Phase II Dose-Finding Study

BMC Gastroenterology
MedicineGastroenterology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy